Variant · Expression
ESR2 underexpression beta-1
CI-VAR-00005069Explore in graph →CIViC 3478
Curated evidence
Evidence by cancer (4 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 27810901
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Malignant Breast Neoplasm4 | ||||||||
| ESR2 underexpression beta-1 | (prognostic) | Prognostic | B | Supports Poor Outcome | 4 | submitted | EID9613In a clinical study including 903 patients, ERalpha negative patients with no expression of beta-1 is significantly correlated with decreased DFS (p < 0.0001). PMID 27810901 · Elebro et al., 2017 · Open in CIViC | civic |
| ESR2 underexpression beta-1 | (prognostic) | Prognostic | B | Supports Poor Outcome | 4 | submitted | EID9618In a clinical study including 177 patients ERalpha positive treated with tamoxifen and fluoxymesterone therapy, nuclear underexpression of beta-1 is significantly associated with decreased RFS (p = 0.… (full text at CIViC) PMID 25288324 · Reese et al., 2014 · Open in CIViC | civic |
| ESR2 underexpression beta-1 | ||||||||
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available